220 related articles for article (PubMed ID: 20423276)
1. Frequent inactivation of hSRBC in ovarian cancers by promoter CpG island hypermethylation.
Tong SY; Ki KD; Lee JM; Kang MJ; Ha TK; Chung SI; Chi SG; Lee SK
Acta Obstet Gynecol Scand; 2010 May; 89(5):629-35. PubMed ID: 20423276
[TBL] [Abstract][Full Text] [Related]
2. Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses.
Lee JH; Byun DS; Lee MG; Ryu BK; Kang MJ; Chae KS; Lee KY; Kim HJ; Park H; Chi SG
Int J Cancer; 2008 Apr; 122(7):1573-84. PubMed ID: 18059034
[TBL] [Abstract][Full Text] [Related]
3. Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers.
Xu XL; Wu LC; Du F; Davis A; Peyton M; Tomizawa Y; Maitra A; Tomlinson G; Gazdar AF; Weissman BE; Bowcock AM; Baer R; Minna JD
Cancer Res; 2001 Nov; 61(21):7943-9. PubMed ID: 11691816
[TBL] [Abstract][Full Text] [Related]
4. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
5. Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation.
Zöchbauer-Müller S; Fong KM; Geradts J; Xu X; Seidl S; End-Pfützenreuter A; Lang G; Heller G; Zielinski CC; Gazdar AF; Minna JD
Oncogene; 2005 Sep; 24(41):6249-55. PubMed ID: 15940253
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
7. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
8. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.
Byun DS; Lee MG; Chae KS; Ryu BG; Chi SG
Cancer Res; 2001 Oct; 61(19):7034-8. PubMed ID: 11585730
[TBL] [Abstract][Full Text] [Related]
9. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.
Czekierdowski A; Czekierdowska S; Danilos J; Czuba B; Sodowski K; Sodowska H; Szymanski M; Kotarski J
J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():53-65. PubMed ID: 18955754
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas.
Byun DS; Cho K; Ryu BK; Lee MG; Kang MJ; Kim HR; Chi SG
Cancer Res; 2003 Nov; 63(21):7068-75. PubMed ID: 14612497
[TBL] [Abstract][Full Text] [Related]
11. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
[TBL] [Abstract][Full Text] [Related]
12. Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer.
Braga Lda C; Silva LM; Ramos AP; Piedade JB; Vidigal PV; Traiman P; da Silva Filho AL
Biomed Pharmacother; 2014 Feb; 68(1):87-91. PubMed ID: 24412083
[TBL] [Abstract][Full Text] [Related]
13. Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers.
Zou B; Chim CS; Zeng H; Leung SY; Yang Y; Tu SP; Lin MC; Wang J; He H; Jiang SH; Sun YW; Yu LF; Yuen ST; Kung HF; Wong BC
Gastroenterology; 2006 Dec; 131(6):1835-43. PubMed ID: 17087954
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of DLC-1 in supratentorial primitive neuroectodermal tumor.
Pang JC; Chang Q; Chung YF; Teo JG; Poon WS; Zhou LF; Kong X; Ng HK
Hum Pathol; 2005 Jan; 36(1):36-43. PubMed ID: 15712180
[TBL] [Abstract][Full Text] [Related]
15. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Kikuchi R; Tsuda H; Kanai Y; Kasamatsu T; Sengoku K; Hirohashi S; Inazawa J; Imoto I
Cancer Res; 2007 Aug; 67(15):7095-105. PubMed ID: 17671176
[TBL] [Abstract][Full Text] [Related]
16. Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation.
Yue W; Dacic S; Sun Q; Landreneau R; Guo M; Zhou W; Siegfried JM; Yu J; Zhang L
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4336-44. PubMed ID: 17671114
[TBL] [Abstract][Full Text] [Related]
17. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers.
Sidiropoulos M; Pampalakis G; Sotiropoulou G; Katsaros D; Diamandis EP
Tumour Biol; 2005; 26(6):324-36. PubMed ID: 16254462
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation paradigm shift: 15-lipoxygenase-1 upregulation in prostatic intraepithelial neoplasia and prostate cancer by atypical promoter hypermethylation.
Kelavkar UP; Harya NS; Hutzley J; Bacich DJ; Monzon FA; Chandran U; Dhir R; O'Keefe DS
Prostaglandins Other Lipid Mediat; 2007 Jan; 82(1-4):185-97. PubMed ID: 17164146
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
